PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 28 No. 5
Pages: 1  2  3  4  
Previous Next
Clinical Psychopharmacology 

Does MDMA Have a Role in Clinical Psychiatry?

By Michael C. Mithoefer, MD | May 6, 2011
Dr Mithoefer is in private practice of psychiatry and clinical research in Mount Pleasant, SC. Dr Mithoefer reports that he receives funding from the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit organization for conducting research, protocol development, and training of other researchers, and for acting as medical monitor for other studies.

Possible mechanisms

While the format of MDMA-assisted psychotherapy and the nondirective therapeutic approach we used are quite different from many existing treatments for PTSD, some elements of what occurs in MDMA-assisted therapy would be easily recognizable to many therapists. The first category of effects discussed above, in which MDMA appears to remove obstacles to effective trauma processing, can be understood in terms used by Foa and colleagues19 to describe obstacles to prolonged exposure therapy: overengagement and underengagement.

(MORE: Ethical Issues in Psychopharmacology)

To be effective, exposure must be accompanied by a degree of emotional engagement or fear activation while avoiding dissociation or overwhelming emotion.20 This has been referred to as working within the optimal arousal zone, or window of tolerance.21-23 During MDMA sessions, we observed that patients with PTSD spontaneously engaged in “imaginal exposure,” and MDMA appeared to allow them to remain within an optimal arousal zone while doing so.

Further trials will determine whether the study results will evolve into clinical applications … it is likely that MDMA may find an important place in the future of psychopharmacology.

The pharmacological effects of MDMA include serotonin release; serotonin type 2 receptor stimulation; and an increase in levels of the neurohormones oxytocin(Drug information on oxytocin), prolactin, and cortisol.24-29 Serotonin release plays an important role in producing the subjective effects of MDMA.30-33 Pretreatment with SSRIs reduces most acute subjective and physiological effects of MDMA, including effects on mood and perception. Serotonin release directly or indirectly leads to an elevation in oxytocin levels, possibly by stimulating serotonin type 1A receptors.24,28,34 Studies suggest that oxytocin plays an important role in stress response, reduces the fear response, and increases social affiliation and trust35-39; thus, elevated oxytocin levels might help patients form a therapeutic alliance and revisit traumatic experiences in an emotionally engaged state.

Elevation in oxytocin levels after MDMA administration has been associated with greater sociability and more gregarious behavior.24 MDMA has recently been shown to decrease perception of negative emotions in others and perception of threat-related signals, such as fear, which might increase social approach behavior.40 It has been postulated that prolactin release following MDMA administration may contribute to a postorgasmic-like sense of relaxation and receptivity.41 The neurocircuitry model of PTSD postulates a deficit in extinction of fear conditioning mediated by the amygdala and the ventromedial prefrontal cortex, a model supported by findings of reduced hippocampal activity and volume, increased activity in the amygdala, and decreased activation of the medial prefrontal cortex in persons with PTSD.42,43

Gamma and colleagues44 used positron emission tomography to measure cerebral blood flow 75 minutes after MDMA was given to healthy volunteers. Their findings showed increases in cerebral blood flow in the ventromedial frontal and occipital cortex and decreases in the left amygdala. MDMA may produce some of its effects through these acute changes in brain activity, which may reverse abnormalities associated with PTSD and thereby allow effective processing of traumatic memories. The nature of the effects is consistent with much of what we observed in our clinical trial.

Pages: 1  2  3  4  
Previous Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by James OBrien | June 03, 2011 10:56 AM EDT

I think enough data is in on EMDR. How about a study of MDMA vs. Prazosin?

by Michael Mithoefer | May 28, 2011 10:52 AM EDT

I appreciate the comments of Rodrigo Figueroa and Jennifer Fauntleroy. I think a study comparing EMDR with MDMA-assisted psychotherapy would be worthwhile. Currently, the resources available for clinical trials of MDMA-assisted psychotherapy are directed toward the kinds of study designs that will be necessary for the FDA to consider approving MDMA for clinical use. If larger studies do lead to approval, then studies comparing MDMA-assisted psychotherapy to other methods of therapy will be important and will be easier to do. There is not an ethical problem in our current studies because we enroll only treatment-resistant patients who have failed to respond to previous treatments (in some cases previous EMDR), and if a participant is in therapy at the time of enrollment they may continue that same therapy during the study.
Michael Mithoefer

by Rodrigo Figueroa | May 21, 2011 7:17 PM EDT

And what about head to head EMDR plus MDMA vs EMDR plus placebo? MDMA alone could be against ethical standards, leaving sick people without an evidence-based treatment.

by jennifer fauntleroy | May 19, 2011 2:33 PM EDT

How about a head to head EMDR vs, MDMA?

Also in this Special Report

Introduction: Looking to the Future of Psychopharmacology

Antidrug Vaccines

Novel Treatment Avenues for Bipolar Depression

Does MDMA Have a Role in Clinical Psychiatry?

Ethical Issues in Psychopharmacology






 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Developmental Psychopathology Comes of Age
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Psychiatry and the Myth of “Medicalization”
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
  • Refinements in ECT Techniques
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy